Fox Run Management L.L.C. Grows Stock Position in BioNTech SE Sponsored ADR $BNTX

Fox Run Management L.L.C. increased its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 242.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,750 shares of the company’s stock after buying an additional 6,906 shares during the quarter. Fox Run Management L.L.C.’s holdings in BioNTech were worth $962,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Financial Consulate Inc. bought a new stake in shares of BioNTech in the 3rd quarter worth about $36,000. Tower Research Capital LLC TRC raised its position in BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. raised its position in BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after purchasing an additional 472 shares during the period. GAMMA Investing LLC lifted its stake in BioNTech by 40.8% in the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after purchasing an additional 227 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its position in shares of BioNTech by 188.1% during the third quarter. Rakuten Securities Inc. now owns 1,043 shares of the company’s stock valued at $103,000 after buying an additional 681 shares during the period. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX stock opened at $108.80 on Friday. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $124.00. The business has a 50-day moving average price of $105.59 and a 200 day moving average price of $103.52. The company has a market capitalization of $24.50 billion, a P/E ratio of -41.37 and a beta of 1.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BNTX. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the stock from $115.00 to $142.00 in a report on Friday, January 16th. TD Cowen reissued a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $140.10.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.